Meijun Liu

Meijun Liu

Auto-generated profile, based on publicly available information

Meijun Liu

Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2026 in British Journal of Dermatology
Verified
Journal Article
Closed access
MLMeijun Liu
Meijun Liu
PDPinzhi Dong
Pinzhi Dong
CYCong Yang
Cong Yang
XXXiaorong Xu
Xiaorong Xu
YWYingnong Wu
Yingnong Wu
MQming qin
ming qin
Although immune-targeted therapies, particularly agents targeting the interleukin (IL)-23/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centred therapies may not fully address the active contribution of epidermal keratinocytes to inflammatory amplification and disease persistence. In this review, we integrate immune-driven inflammation and epidermal amplification mechanisms from a loop- and network-based perspective, and ­propose an immune–epidermal dual-targeting framework centred on proinflammatory feedback between immune cells and keratinocytes. We systematically summarize three potential implementation routes: combination therapy, single-agent dual targeting and blockade of bridging nodes within immune–epidermal feedback circuits. We further discuss the potential roles and realistic boundaries of artificial intelligence and multi-omics analysis, organoids and engineered skin models, and precision local delivery technologies in target discovery, mechanistic validation and therapeutic translation. Importantly, this framework is not intended to replace existing therapeutic paradigms, but rather to refine their mechanistic interpretation and extend future therapeutic strategies. It may provide additional translational opportunities for stratified, stage-specific and precision management of psoriasis, although several components remain at the stage of mechanistic research and clinical validation.